1-7 of 7
Sueh-li Lim
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Minimal residual disease (MRD)-negative outcomes following a novel, in vivo gene therapy generating anti–B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cells in patients with relapsed and refractory multiple myeloma (RRMM): Preliminary results from inMMyCAR, the first-in-human phase 1 study of KLN-1010

Free
Simon Harrison, Phoebe Joy Ho, Sueh-Li Lim, Stephanie Talam, Hannah Pahl, Dharmesh Dingar, Scott Currence, Travis Quigley, Andrew Spencer
Journal: Blood
Blood (2025) 146 (Supplement 2): LBA-1.
https://doi.org/10.1182/blood-2025-LBA-1
Published: 2025
Journal Articles

Updated results from the frailty-stratified, randomised controlled bayesian adaptive trial of bortezomib versus lenalidomide in transplant ineligible myeloma (TI NDMM) – the FRAIL-m study (AMaRC 19-01; ALLG MM22)

Free
Sueh-Li Lim, John Reynolds, Lucy Pemberton, Tricia Wright, Sophie Lee, Peter Mollee, Anita C. Shetty, Yu Jin Kim, Weston Helen, Byard Nina, Khoa Le, Zoe McQuilten, Hang Quach, Andrew Spencer
Journal: Blood
Blood (2025) 146 (Supplement 1): 5842.
https://doi.org/10.1182/blood-2025-5842
Published: 2025
Journal Articles

An immune-therapeutic salvage strategy for ‘functional’ high-risk (FHR) multiple myeloma (MM) incorporating iberdomide, isatuximab, and dexamethasone – the IBIS study amarc 20-01.

Free
Sueh-Li Lim, Sridurga Mithraprabhu, John Reynolds, Wojciech Janowski, Noemi Horvath, Hang Quach, Philip Campbell, Georgia McCaughan, Yu Jin Kim, Thalia Peres Suarez, Sophie Lee, Phillip Wong, Byard Nina, Priyanka Meet, Khoa Le, Andrew Spencer
Journal: Blood
Blood (2025) 146 (Supplement 1): 5841.
https://doi.org/10.1182/blood-2025-5841
Published: 2025
Journal Articles

A Phase I/II Study of AZD0305, a Novel Antibody-Drug Conjugate (ADC) Targeting GPRC5D, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Free
Sueh-Li Lim, Bradley Augustson, Hira S Mian, Edward A. Stadtmauer, Shinsuke Iida, Michael Slade, Saswati Hazra, Kamal Chamoun, Patricia Cheung, Jamal Saeh, Nina Shah, Amrita Y Krishnan
Journal: Blood
Blood (2024) 144 (Supplement 1): 2000.2.
https://doi.org/10.1182/blood-2024-207816
Published: 2024
Journal Articles

Initial Results from the Frailty-Stratified, Randomised Controlled Bayesian Adaptive Trial of Bortezomib Versus Lenalidomide in Transplant Ineligible Myeloma (TI-NDMM) - the FRAIL-M Study (AMaRC 19-01; ALLG MM22)

Free
Sueh-Li Lim, John Reynolds, Lucy Pemberton, Tricia Wright, Sophie Hyesuk Lee, Peter Mollee, Anita C Shetty, Helen Weston, Nina Byard, Khoa Le, Zoe K McQuilten, Hang Quach, Andrew Spencer
Journal: Blood
Blood (2024) 144 (Supplement 1): 4755.
https://doi.org/10.1182/blood-2024-209640
Published: 2024
Journal Articles

Secondary Analysis of the MM21 Trial: Response Adaptive Salvage Treatment with Daratumumab-Lenalidomide-Dexamethasone (DRd) for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy

Free
Sueh-li Lim, John Reynolds, Hang Quach, Anna Hutchinson, Ian H Kerridge, Jane Estell, Craig wallington-Gates, Anna Kalff, Flora Yuen, Andrew Spencer
Journal: Blood
Blood (2022) 140 (Supplement 1): 10174–10176.
https://doi.org/10.1182/blood-2022-170697
Published: 2022
Journal Articles

Preliminary Analysis of the MM21 Trial: Response Adaptive Salvage Treatment with Daratumumab-Lenalidomide-Dexamethasone (DRd) for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy

Free
Sueh-li Lim, John Reynolds, Hang Quach, Anna Hutchinson, Ian H Kerridge, Jane Estell, Wojt Janowski, Craig Thomas Wallington-Beddoe, Anna Kalff, Flora Yuen, Andrew Spencer
Journal: Blood
Blood (2021) 138 (Supplement 1): 1665.
https://doi.org/10.1182/blood-2021-152102
Published: 2021